دورية أكاديمية
Hepatopulmonary Syndrome: A Comprehensive Review.
العنوان: | Hepatopulmonary Syndrome: A Comprehensive Review. |
---|---|
المؤلفون: | Qasim A; Internal Medicine, BronxCare Health System, New York, USA., Jyala A; Internal Medicine, BronxCare Health System, New York, USA., Shrivastava S; Internal Medicine, BronxCare Health System, New York, USA., Allena N; Pulmonary Medicine, BronxCare Health System, New York, USA., Ghazanfar H; Internal Medicine, BronxCare Health System, New York, USA., Bhatt V; Medicine and Surgery, BronxCare Health System, New York, USA., Ali HR; Medicine, American University of the Caribbean School of Medicine, Miramar, USA., Vakde T; Pulmonary and Critical Care, BronxCare Health System, New York, USA., Patel H; Internal Medicine, BronxCare Health System, New York, USA. |
المصدر: | Cureus [Cureus] 2024 Jul 23; Vol. 16 (7), pp. e65204. Date of Electronic Publication: 2024 Jul 23 (Print Publication: 2024). |
نوع المنشور: | Journal Article; Review |
اللغة: | English |
بيانات الدورية: | Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Palo Alto, CA : Cureus, Inc. |
مستخلص: | Hepatopulmonary syndrome (HPS) is defined by abnormally dilated blood vessels and shunts within the lungs, leading to impaired oxygen exchange. This condition results from intricate interactions between the liver, the gastrointestinal system, and the lungs. This complex system primarily affects pulmonary endothelial, immunomodulatory, and respiratory epithelial cells. Consequently, this contributes to pathological pulmonary changes characteristic of HPS. A classification system based on the severity of oxygen deficiency has been proposed for grading the physiological dysfunction of HPS. Contrast-enhanced echocardiography is considered the primary radiological evaluation for identifying abnormal blood vessel dilations within the lungs, which, combined with an elevated alveolar-arterial gradient, is essential for making the diagnosis. Liver transplantation is the sole effective definitive treatment that can reverse the course of the condition. Despite often being symptomless, HPS carries a significant risk of mortality before transplantation, regardless of the severity of liver disease. Meanwhile, there is varying data regarding survival rates following liver transplantation. The adoption of the model for end-stage liver disease (MELD) standard exception policy has notably improved the results for individuals with HPS compared to the period before MELD was introduced. This review offers a summary of the present understanding, highlighting recent advancements in the diagnosis and treatment of HPS. Furthermore, it aims to augment comprehension of the condition's fundamental mechanisms through insights derived from experimental models and translational research. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Qasim et al.) |
References: | Am J Transplant. 2014 Jun;14(6):1391-9. (PMID: 24730359) Am J Cardiol. 2004 Aug 15;94(4):525-8. (PMID: 15325947) Panminerva Med. 2003 Jun;45(2):95-8. (PMID: 12855933) Acta Gastroenterol Belg. 2013 Jun;76(2):241-5. (PMID: 23898563) Circulation. 2002 Feb 12;105(6):e47. (PMID: 11839642) Curr Opin Anaesthesiol. 2010 Apr;23(2):145-50. (PMID: 20124995) Ann Hepatol. 2007 Jul-Sep;6(3):135-42. (PMID: 17786138) Chest. 1981 Nov;80(5):570-4. (PMID: 7297148) Chest. 1977 Sep;72(3):305-9. (PMID: 891282) Eur Respir J. 2022 Aug 4;60(2):. (PMID: 34949701) Gastroenterology. 1995 Oct;109(4):1283-8. (PMID: 7557096) Pediatr Transplant. 2008 May;12(3):353-7. (PMID: 18435611) Chest. 1993 Aug;104(2):515-21. (PMID: 8101797) Am J Respir Crit Care Med. 2013 Jan 15;187(2):133-43. (PMID: 23155142) Curr Opin Anaesthesiol. 2010 Apr;23(2):133-8. (PMID: 20019600) Echocardiography. 2017 Oct;34(10):1439-1446. (PMID: 28840954) Gastroenterology Res. 2021 Aug;14(4):252-258. (PMID: 34527095) N Engl J Med. 2008 May 29;358(22):2378-87. (PMID: 18509123) Clin Gastroenterol Hepatol. 2021 Nov;19(11):2370-2378. (PMID: 33007510) Eur J Gastroenterol Hepatol. 2010 Aug;22(8):1006-12. (PMID: 20101183) Curr Gastroenterol Rep. 2000 Feb;2(1):40-5. (PMID: 10981002) Eur J Clin Invest. 1987 Feb;17(1):7-11. (PMID: 3106053) Bosn J Basic Med Sci. 2017 Nov 20;17(4):276-285. (PMID: 28759737) J Hepatol. 2001 May;34(5):651-7. (PMID: 11434610) Haemophilia. 2008 Nov;14(6):1269-80. (PMID: 19141168) Chest. 1994 Nov;106(5):1387-90. (PMID: 7956388) Eur Respir J. 2004 Nov;24(5):861-80. (PMID: 15516683) Mol Imaging Radionucl Ther. 2020 Feb 17;29(1):1-6. (PMID: 32079381) Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1525-31. (PMID: 10556115) Compr Physiol. 2018 Mar 25;8(2):711-729. (PMID: 29687908) Rev Esp Enferm Dig. 2017 May;109(5):335-343. (PMID: 28301945) Curr Gastroenterol Rep. 2016 Jun;18(6):29. (PMID: 27098816) Chest. 1992 Oct;102(4):1161-6. (PMID: 1395761) BMC Gastroenterol. 2006 Apr 25;6:15. (PMID: 16638132) Radiographics. 2009 May-Jun;29(3):825-37. (PMID: 19448118) J Chin Med Assoc. 2005 Nov;68(11):500-5. (PMID: 16323392) Clin Chest Med. 1996 Mar;17(1):1-15. (PMID: 8665783) Transplant Proc. 2008 Dec;40(10):3512-6. (PMID: 19100426) Acta Neurol Scand. 2014 Mar;129(3):192-7. (PMID: 23962120) Ann Hepatol. 2015 May-Jun;14(3):354-60. (PMID: 25864216) J Gastroenterol Hepatol. 2013 Feb;28(2):213-9. (PMID: 23190201) Hepatology. 2019 Jan;69(1):270-281. (PMID: 30070715) Am J Physiol Lung Cell Mol Physiol. 2002 Aug;283(2):L346-53. (PMID: 12114196) Hepatology. 2004 Sep;40(3):660-6. (PMID: 15349905) Thorax. 1992 Nov;47(11):897-902. (PMID: 1465744) Am J Respir Crit Care Med. 2020 Jun 15;201(12):1575-1578. (PMID: 32083953) Eur Respir J. 2009 May;33(5):1186-94. (PMID: 19407052) Pediatrics. 2008 Mar;121(3):e522-7. (PMID: 18310172) Lancet. 2004 May 1;363(9419):1461-8. (PMID: 15121411) Radiology. 1988 Dec;169(3):663-9. (PMID: 3186989) Gut. 2002 Dec;51(6):853-9. (PMID: 12427789) Gastroenterology. 2008 Oct;135(4):1168-75. (PMID: 18644373) Ann Intern Med. 1995 Apr 1;122(7):521-9. (PMID: 7872588) Am J Physiol. 1995 Nov;269(5 Pt 1):L668-72. (PMID: 7491987) Chest. 2000 Sep;118(3):615-24. (PMID: 10988181) |
فهرسة مساهمة: | Keywords: alveolar gas exchange; arterial blood gas; hepatopulmonary syndrome; model for end-stage liver disease (meld); review article |
تواريخ الأحداث: | Date Created: 20240823 Latest Revision: 20240824 |
رمز التحديث: | 20240826 |
مُعرف محوري في PubMed: | PMC11340781 |
DOI: | 10.7759/cureus.65204 |
PMID: | 39176346 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2168-8184 |
---|---|
DOI: | 10.7759/cureus.65204 |